Skip to main content
NASDAQ:VCYT

Veracyte Competitors

$35.20
-1.26 (-3.46 %)
(As of 05/13/2021 12:00 AM ET)
Add
Compare
Today's Range
$33.66
$38.25
50-Day Range
$36.46
$56.62
52-Week Range
$22.69
$86.03
Volume1.34 million shs
Average Volume951,368 shs
Market Capitalization$2.37 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.77

Competitors

Veracyte (NASDAQ:VCYT) Vs. NTRA, NVTA, CDNA, BNR, FLGT, and GTH

Should you be buying VCYT stock or one of its competitors? Companies in the industry of "medical laboratories" are considered alternatives and competitors to Veracyte, including Natera (NTRA), Invitae (NVTA), CareDx (CDNA), Burning Rock Biotech (BNR), Fulgent Genetics (FLGT), and Genetron (GTH).

Veracyte (NASDAQ:VCYT) and Natera (NASDAQ:NTRA) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, institutional ownership, profitability and risk.

Valuation & Earnings

This table compares Veracyte and Natera's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$120.37 million19.67$-12,600,000.00($0.27)-130.37
Natera$302.33 million25.87$-124,830,000.00($1.99)-44.68

Veracyte has higher earnings, but lower revenue than Natera. Veracyte is trading at a lower price-to-earnings ratio than Natera, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Veracyte and Natera, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Veracyte11602.63
Natera01902.90

Veracyte presently has a consensus price target of $55.5714, suggesting a potential upside of 57.87%. Natera has a consensus price target of $114.70, suggesting a potential upside of 28.99%. Given Veracyte's higher possible upside, equities research analysts plainly believe Veracyte is more favorable than Natera.

Institutional & Insider Ownership

94.9% of Natera shares are held by institutional investors. 8.3% of Veracyte shares are held by insiders. Comparatively, 9.3% of Natera shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Volatility and Risk

Veracyte has a beta of 0.77, indicating that its stock price is 23% less volatile than the S&P 500. Comparatively, Natera has a beta of 1.66, indicating that its stock price is 66% more volatile than the S&P 500.

Profitability

This table compares Veracyte and Natera's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Veracyte-30.46%-12.27%-10.95%
Natera-52.11%-53.39%-25.89%

Summary

Natera beats Veracyte on 8 of the 14 factors compared between the two stocks.

Invitae (NYSE:NVTA) and Veracyte (NASDAQ:VCYT) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, earnings, analyst recommendations, profitability and risk.

Risk and Volatility

Invitae has a beta of 2.11, suggesting that its stock price is 111% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings for Invitae and Veracyte, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invitae03402.57
Veracyte11602.63

Invitae presently has a consensus target price of $46.1667, suggesting a potential upside of 76.95%. Veracyte has a consensus target price of $55.5714, suggesting a potential upside of 57.87%. Given Invitae's higher probable upside, equities research analysts clearly believe Invitae is more favorable than Veracyte.

Valuation and Earnings

This table compares Invitae and Veracyte's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invitae$216.82 million24.05$-241,960,000.00($2.28)-11.44
Veracyte$120.37 million19.67$-12,600,000.00($0.27)-130.37

Veracyte has lower revenue, but higher earnings than Invitae. Veracyte is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

78.6% of Invitae shares are held by institutional investors. 2.9% of Invitae shares are held by insiders. Comparatively, 8.3% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Profitability

This table compares Invitae and Veracyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Invitae-183.50%-81.19%-37.28%
Veracyte-30.46%-12.27%-10.95%

Summary

Veracyte beats Invitae on 8 of the 14 factors compared between the two stocks.

Veracyte (NASDAQ:VCYT) and CareDx (NASDAQ:CDNA) are both mid-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.

Risk & Volatility

Veracyte has a beta of 0.77, meaning that its share price is 23% less volatile than the S&P 500. Comparatively, CareDx has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings and price targets for Veracyte and CareDx, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Veracyte11602.63
CareDx01413.00

Veracyte currently has a consensus target price of $55.5714, indicating a potential upside of 57.87%. CareDx has a consensus target price of $75.6667, indicating a potential upside of 17.84%. Given Veracyte's higher possible upside, research analysts clearly believe Veracyte is more favorable than CareDx.

Profitability

This table compares Veracyte and CareDx's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Veracyte-30.46%-12.27%-10.95%
CareDx-11.79%-10.95%-7.94%

Valuation & Earnings

This table compares Veracyte and CareDx's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$120.37 million19.67$-12,600,000.00($0.27)-130.37
CareDx$127.07 million26.30$-21,970,000.00($0.52)-123.48

Veracyte has higher earnings, but lower revenue than CareDx. Veracyte is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Summary

CareDx beats Veracyte on 8 of the 13 factors compared between the two stocks.

Burning Rock Biotech (NASDAQ:BNR) and Veracyte (NASDAQ:VCYT) are both mid-cap business services companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, institutional ownership and dividends.

Insider & Institutional Ownership

15.8% of Burning Rock Biotech shares are owned by institutional investors. 8.3% of Veracyte shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Earnings & Valuation

This table compares Burning Rock Biotech and Veracyte's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Burning Rock BiotechN/AN/AN/AN/AN/A
Veracyte$120.37 million19.67$-12,600,000.00($0.27)-130.37

Burning Rock Biotech has higher earnings, but lower revenue than Veracyte.

Profitability

This table compares Burning Rock Biotech and Veracyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Burning Rock BiotechN/AN/AN/A
Veracyte-30.46%-12.27%-10.95%

Analyst Recommendations

This is a summary of current ratings for Burning Rock Biotech and Veracyte, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Burning Rock Biotech00303.00
Veracyte11602.63

Burning Rock Biotech currently has a consensus target price of $32.30, indicating a potential upside of 11.96%. Veracyte has a consensus target price of $55.5714, indicating a potential upside of 57.87%. Given Veracyte's higher possible upside, analysts clearly believe Veracyte is more favorable than Burning Rock Biotech.

Summary

Burning Rock Biotech beats Veracyte on 5 of the 9 factors compared between the two stocks.

Fulgent Genetics (NASDAQ:FLGT) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation and analyst recommendations.

Analyst Recommendations

This is a summary of recent recommendations for Fulgent Genetics and Veracyte, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fulgent Genetics12202.20
Veracyte11602.63

Fulgent Genetics currently has a consensus price target of $74.40, indicating a potential upside of 10.30%. Veracyte has a consensus price target of $55.5714, indicating a potential upside of 57.87%. Given Veracyte's stronger consensus rating and higher probable upside, analysts plainly believe Veracyte is more favorable than Fulgent Genetics.

Volatility & Risk

Fulgent Genetics has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500. Comparatively, Veracyte has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.

Valuation & Earnings

This table compares Fulgent Genetics and Veracyte's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulgent Genetics$32.53 million60.14$-410,000.00$0.023,372.50
Veracyte$120.37 million19.67$-12,600,000.00($0.27)-130.37

Fulgent Genetics has higher earnings, but lower revenue than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than Fulgent Genetics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Fulgent Genetics and Veracyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fulgent Genetics35.31%43.81%36.82%
Veracyte-30.46%-12.27%-10.95%

Institutional and Insider Ownership

33.4% of Fulgent Genetics shares are held by institutional investors. 45.0% of Fulgent Genetics shares are held by insiders. Comparatively, 8.3% of Veracyte shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Fulgent Genetics beats Veracyte on 10 of the 14 factors compared between the two stocks.

Veracyte (NASDAQ:VCYT) and Genetron (NASDAQ:GTH) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, earnings, dividends and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Veracyte and Genetron, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Veracyte11602.63
Genetron00203.00

Veracyte currently has a consensus price target of $55.5714, suggesting a potential upside of 57.87%. Genetron has a consensus price target of $19.50, suggesting a potential upside of 8.94%. Given Veracyte's higher possible upside, analysts plainly believe Veracyte is more favorable than Genetron.

Insider & Institutional Ownership

19.6% of Genetron shares are owned by institutional investors. 8.3% of Veracyte shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Veracyte and Genetron's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Veracyte-30.46%-12.27%-10.95%
GenetronN/AN/AN/A

Earnings and Valuation

This table compares Veracyte and Genetron's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Veracyte$120.37 million19.67$-12,600,000.00($0.27)-130.37
Genetron$45.68 million34.83$-95,470,000.00N/AN/A

Veracyte has higher revenue and earnings than Genetron.

Summary

Genetron beats Veracyte on 6 of the 11 factors compared between the two stocks.


Veracyte Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Natera logo
NTRA
Natera
1.7$88.92-2.0%$7.82 billion$302.33 million-37.36Analyst Report
Gap Up
Invitae logo
NVTA
Invitae
1.6$26.09-2.6%$5.21 billion$216.82 million-6.71Analyst Report
CareDx logo
CDNA
CareDx
1.2$64.21-1.9%$3.34 billion$127.07 million-139.58Analyst Report
Insider Selling
BNR
Burning Rock Biotech
1.1$28.85-3.5%$3.02 billionN/A0.00
Fulgent Genetics logo
FLGT
Fulgent Genetics
1.6$67.45-1.0%$1.96 billion$32.53 million33.39
GTH
Genetron
0.4$17.90-4.9%$1.59 billion$45.68 million0.00News Coverage
Castle Biosciences logo
CSTL
Castle Biosciences
1.9$50.07-4.1%$1.25 billion$51.87 million-294.51Earnings Announcement
Analyst Report
Analyst Revision
RadNet logo
RDNT
RadNet
1.3$23.47-1.8%$1.23 billion$1.15 billion-111.76Earnings Announcement
Analyst Downgrade
Renalytix AI logo
RNLX
Renalytix AI
0.7$28.70-0.1%$1.03 billionN/A-179.38
DermTech logo
DMTK
DermTech
1.6$29.14-6.1%$842.32 million$3.36 million-17.24
Personalis logo
PSNL
Personalis
1.6$18.15-2.3%$796.93 million$65.21 million-17.12Analyst Report
Celcuity logo
CELC
Celcuity
1.0$25.99-3.8%$328.70 millionN/A-30.58Earnings Announcement
Centogene logo
CNTG
Centogene
1.2$9.24-1.4%$183.52 million$54.64 million-6.33
Exagen logo
XGN
Exagen
1.7$12.40-3.6%$157.11 million$40.39 million-1.01Earnings Announcement
News Coverage
Enzo Biochem logo
ENZ
Enzo Biochem
0.7$2.96-2.4%$142.76 million$76.02 million-6.88
Progenity logo
PROG
Progenity
1.8$2.35-1.7%$141.80 millionN/A0.00Gap Up
OpGen logo
OPGN
OpGen
1.3$1.99-13.1%$76.15 million$3.50 million-0.98News Coverage
Gap Down
Biocept logo
BIOC
Biocept
1.2$4.28-11.2%$57.37 million$5.53 million-1.06Gap Down
AnPac Bio-Medical Science logo
ANPC
AnPac Bio-Medical Science
0.7$4.09-4.9%$45.81 million$1.56 million-2.52Upcoming Earnings
Psychemedics logo
PMD
Psychemedics
0.8$6.55-0.3%$36.26 million$37.68 million-9.49
AMS
American Shared Hospital Services
0.1$2.36-7.2%$13.69 million$20.60 million-23.60News Coverage
Gap Up
This page was last updated on 5/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.